Tamsulosin

Evidence Level: L5

Predicted Indications: 10

Tamsulosin
Tamsulosin: From Lower Urinary Tract Symptoms to Ambras Type Hypertrichosis Universalis Congenita

## Pharmacist Assessment Report

Tamsulosin: From Lower Urinary Tract Symptoms to Ambras Type Hypertrichosis Universalis Congenita

One-Sentence Summary

Tamsulosin is an alpha-1A/1D adrenoceptor antagonist used for lower urinary tract symptoms. The TxGNN model predicts it may be effective for Ambras type hypertrichosis universalis congenita, but no clinical trials and no publications support this prediction. It is a model-only signal with no identified pharmacological rationale.

Quick Overview

Item	Content
Original Indication	Lower urinary tract symptoms (taken from the prediction rationale; the US license records list no indication text)
Predicted New Indication	Ambras type hypertrichosis universalis congenita
TxGNN Prediction Score	99.996% (rank 246)
Evidence Level	L5 (model prediction only)
US Market Status	✓ Marketed
Number of NDAs	20 (all listed licenses are generic ANDAs)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the record. Tamsulosin is an alpha-1A/1D adrenoceptor antagonist, and its established use is symptomatic treatment of lower urinary tract symptoms.

No plausible link was identified between the two conditions. Ambras syndrome is a rare congenital disorder tied to chromosome 8q22 rearrangements that affect regulation of TRPS1. Alpha-1 adrenergic blockade has no established role in this pathway or in hair-growth regulation.

The high score most likely reflects proximity in the knowledge graph to related hair phenotypes, not a pharmacological signal. The other top predictions follow the same pattern. They include hypertrichosis, hair shaft abnormalities, hypotrichosis, alopecia, and Dandy-Walker malformation syndromes, and none has a mechanistic rationale or supporting evidence. Hypotrichosis simplex of the scalp is the phenotypic opposite of hypertrichosis, yet it also ranks high, which suggests the graph signal is not specific.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

The license records do not include approved indication text, so that column is omitted. The first five of 20 listed licenses are shown.

Authorization Number	Product Name	Dosage Form	Manufacturer
ANDA202433	Tamsulosin Hydrochloride	Capsule	Cardinal Health 107, LLC
ANDA207405	Tamsulosin Hydrochloride	Capsule	Chartwell RX, LLC
ANDA202433	Tamsulosin Hydrochloride	Capsule	Northwind Health Company, LLC
ANDA202433	Tamsulosin Hydrochloride	Capsule	Aurobindo Pharma Limited
ANDA090931	Tamsulosin Hydrochloride	Capsule	Proficient Rx LP

The only route of administration listed is oral (capsule).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by the graph model score. There are no trials or publications, and no mechanistic link between alpha-1A/1D blockade and Ambras syndrome. The 20 publications retrieved for another predicted indication (periodontal malformation syndrome, rank 3) concern periodontitis in general and do not mention tamsulosin, so they do not raise the evidence level.

To proceed, the following is needed:

Any tamsulosin-specific mechanistic or preclinical evidence for hair-follicle or TRPS1-related biology
Mechanism of action data from DrugBank
FDA package insert warnings and contraindications, which are currently missing and block safety screening
Pharmacoepidemiology data on hair outcomes in tamsulosin users, if the hair-related predictions are to be pursued
Route compatibility and similarity-to-original assessments, which are still pending
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.